Posted by Michael Wonder on 11 Sep 2024
Pierre Fabre Laboratories receives European Commission approval for Braftovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation
30 August 2024 - European approval is based on results from the Phase 2 PHAROS trial, which showed a meaningful clinical benefit to BRAF V600E mutated advanced non-small cell lung cancer patients with an objective response rate of 75% in treatment naïve patients and 46% in previously treated patients.
Pierre Fabre Laboratories announced today that the European Commission has approved Braftovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
